Tumor-derived extracellular vesicles for diagnosis of early-stage ovarian cancer

Ended Definitive Contract Awarded Last action

Contract number
75N91025C00044
Awardee
Awarding agency
Obligated
$299,828

Award facts

Contract value 100% obligated
$299,828.00 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Set-aside
Total Small Business
Competition
Full and Open Competition after exclusion of sources · 55 offers Negotiated Proposal / Quote
Pricing
Firm Fixed Price
Place of performance
Missoula, MT 59802, USA
Legislative mandates

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Supplemental Agreement for work within scope P00001 -$55,000
Original award $354,828

About this award

The National Cancer Institute awarded a $299,828 definitive contract to FYR Diagnostics Inc. for development of tumor-derived extracellular vesicles for diagnosis of early-stage ovarian cancer on September 15, 2025, under a total small business set-aside.

The contract is firm fixed price with an ultimate completion date of September 14, 2026. Place of performance is Missoula, MT.

Quick answers

Who was awarded contract 75N91025C00044?

75N91025C00044 was awarded to FYR Diagnostics Inc. by National Cancer Institute (National Institutes of Health) on September 15, 2025.

How much is contract 75N91025C00044 worth?

The government has obligated $299,828 on 75N91025C00044.

Was contract 75N91025C00044 competed?

The extent of competition for 75N91025C00044 was full and open competition after exclusion of sources. The government received 55 offers. It was set aside: Total Small Business.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award